NAGA and Fabry disease: There was no immunological cross-reactivity between the modified NAGA and α-galactosidase A, and the modified NAGA did not react to serum from a patient with FD treated with recombinant α-galactosidase A. The enzyme cleaved Gb3 accumulated in cultured fibroblasts from a patient with FD.